US 12,668,620 B2Granted

Neutralizing monoclonal anti-VP1 antibodies to BK virus

AssigneeIcahn School of Medicine at Mount Sinai

InventorsThomas M. Moran, Thomas A. Kraus, James A. Duty, Domenico Tortorella

Life of this patent

Estimating the term…

Abstract

Provided herein are monoclonal antibodies targeting VP1 of polyomaviruses including BK virus. Also provided are methods of treating or preventing polyomavirus infections using one or more antibodies.

Claims20

Dependent claims

An isolated anti-VP1 antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) having three complementarity determining regions (CDRs) of HCDR1, HCDR2, and HCDR3, and a light chain variable region (VL) having three CDRs of LCDR1, LCDR2, and LCDR3, wherein:

(a) HCDR1 comprises SEQ ID NO:
113,
HCDR2 comprises SEQ ID NO:
114,
HCDR3 comprises SEQ ID NO:
115,
LCDR1 comprises SEQ ID NO:
116,
LCDR2 comprises SEQ ID NO:
117, and
LCDR3 comprises SEQ ID NO:
118;
(b) HCDR1 comprises SEQ ID NO:
97,
HCDR2 comprises SEQ ID NO:
98,
HCDR3 comprises SEQ ID NO:
99, 131, or 139,
LCDR1 comprises SEQ ID NO:
100,
LCDR2 comprises SEQ ID NO:
101, and
LCDR3 comprises SEQ ID NO:
102;
(c) HCDR1 comprises SEQ ID NO:
1,
HCDR2 comprises SEQ ID NO:
2,
HCDR3 comprises SEQ ID NO:
3,
LCDR1 comprises SEQ ID NO:
4,
LCDR2 comprises SEQ ID NO:
5, and
LCDR3 comprises SEQ ID NO:
6;
(d) HCDR1 comprises SEQ ID NO:
9,
HCDR2 comprises SEQ ID NO:
10,
HCDR3 comprises SEQ ID NO:
11,
LCDR1 comprises SEQ ID NO:
12,
LCDR2 comprises SEQ ID NO:
13, and
LCDR3 comprises SEQ ID NO:
14;
(e) HCDR1 comprises SEQ ID NO:
17,
HCDR2 comprises SEQ ID NO:
18,
HCDR3 comprises SEQ ID NO:
19,
LCDR1 comprises SEQ ID NO:
20,
LCDR2 comprises SEQ ID NO:
21, and
LCDR3 comprises SEQ ID NO:
22;
(f) HCDR1 comprises SEQ ID NO:
25,
HCDR2 comprises SEQ ID NO:
26,
HCDR3 comprises SEQ ID NO:
27,
LCDR1 comprises SEQ ID NO:
28,
LCDR2 comprises SEQ ID NO:
29, and
LCDR3 comprises SEQ ID NO:
30;
(g) HCDR1 comprises SEQ ID NO:
33,
HCDR2 comprises SEQ ID NO:
34,
HCDR3 comprises SEQ ID NO:
35,
LCDR1 comprises SEQ ID NO:
36,
LCDR2 comprises SEQ ID NO:
37, and
LCDR3 comprises SEQ ID NO:
38;
(h) HCDR1 comprises SEQ ID NO:
41,
HCDR2 comprises SEQ ID NO:
42,
HCDR3 comprises SEQ ID NO:
43,
LCDR1 comprises SEQ ID NO:
44,
LCDR2 comprises SEQ ID NO:
45, and
LCDR3 comprises SEQ ID NO:
46;
(i) HCDR1 comprises SEQ ID NO:
49,
HCDR2 comprises SEQ ID NO:
50,
HCDR3 comprises SEQ ID NO:
51,
LCDR1 comprises SEQ ID NO:
52,
LCDR2 comprises SEQ ID NO:
53, and
LCDR3 comprises SEQ ID NO:
54;
(j) HCDR1 comprises SEQ ID NO:
65,
HCDR2 comprises SEQ ID NO:
66,
HCDR3 comprises SEQ ID NO:
67,
LCDR1 comprises SEQ ID NO:
68,
LCDR2 comprises SEQ ID NO:
69, and
LCDR3 comprises SEQ ID NO:
70;
(k) HCDR1 comprises SEQ ID NO:
73,
HCDR2 comprises SEQ ID NO:
74,
HCDR3 comprises SEQ ID NO:
75,
LCDR1 comprises SEQ ID NO:
76,
LCDR2 comprises SEQ ID NO:
77, and
LCDR3 comprises SEQ ID NO:
78;
(l) HCDR1 comprises SEQ ID NO:
81,
HCDR2 comprises SEQ ID NO:
82,
HCDR3 comprises SEQ ID NO:
83,
LCDR1 comprises SEQ ID NO:
84,
LCDR2 comprises SEQ ID NO:
85, and
LCDR3 comprises SEQ ID NO:
86;
(m) HCDR1 comprises SEQ ID NO:
89,
HCDR2 comprises SEQ ID NO:
90,
HCDR3 comprises SEQ ID NO:
91,
LCDR1 comprises SEQ ID NO:
92,
LCDR2 comprises SEQ ID NO:
93, and
LCDR3 comprises SEQ ID NO:
94;
(n) HCDR1 comprises SEQ ID NO:
105,
HCDR2 comprises SEQ ID NO:
106,
HCDR3 comprises SEQ ID NO:
107,
LCDR1 comprises SEQ ID NO:
108,
LCDR2 comprises SEQ ID NO:
109, and
LCDR3 comprises SEQ ID NO:
110;
(o) HCDR1 comprises SEQ ID NO:
121,
HCDR2 comprises SEQ ID NO:
122,
HCDR3 comprises SEQ ID NO:
123,
LCDR1 comprises SEQ ID NO:
124,
LCDR2 comprises SEQ ID NO:
125, and
LCDR3 comprises SEQ ID NO:
126;
(p) HCDR1 comprises SEQ ID NO:
145,
HCDR2 comprises SEQ ID NO:
146,
HCDR3 comprises SEQ ID NO:
147,
LCDR1 comprises SEQ ID NO:
148,
LCDR2 comprises SEQ ID NO:
149, and
LCDR3 comprises SEQ ID NO:
150;
(q) HCDR1 comprises SEQ ID NO:
153,
HCDR2 comprises SEQ ID NO:
154,
HCDR3 comprises SEQ ID NO:
155,
LCDR1 comprises SEQ ID NO:
156,
LCDR2 comprises SEQ ID NO:
157, and
LCDR3 comprises SEQ ID NO:
158;
(r) HCDR1 comprises SEQ ID NO:
161,
HCDR2 comprises SEQ ID NO:
162,
HCDR3 comprises SEQ ID NO:
163,
LCDR1 comprises SEQ ID NO:
164,
LCDR2 comprises SEQ ID NO:
165, and
LCDR3 comprises SEQ ID NO:
166;
(s) HCDR1 comprises SEQ ID NO:
169,
HCDR2 comprises SEQ ID NO:
170,
HCDR3 comprises SEQ ID NO:
171,
LCDR1 comprises SEQ ID NO:
172,
LCDR2 comprises SEQ ID NO:
173, and
LCDR3 comprises SEQ ID NO:
174;
or
(t) HCDR1 comprises SEQ ID NO:
177,
HCDR2 comprises SEQ ID NO:
178,
HCDR3 comprises SEQ ID NO:
179,
LCDR1 comprises SEQ ID NO:
180,
LCDR2 comprises SEQ ID NO:
181, and
LCDR3 comprises SEQ ID NO:
182.

238 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/549,974Filed 11 Mar 2022 · us provisional application
Priority: 12 Mar 2021
Published: US 2025/0304658 A12 Oct 2025
Granted: 30 Jun 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 16/081
Against material from viruses: dNA viruses
C07K 16/084
DNA viruses: papillomaviridae ; Polyomaviridae , e.g. SV40, BK virus or JC virus
A61K 31/343
Having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide: condensed with a carbocyclic ring, e.g. coumaran,…
A61K 31/366
Lactones: having six-membered rings, e.g. delta-lactones

Family

Application63/160,678Us provisional application · filed 12 Mar 2021
US 2025/0304658 A1Pre-grant publication · published 2 Oct 2025
US 12,668,620 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Provided herein are monoclonal antibodies targeting VP1 of polyomaviruses including BK virus. Also provided are methods of treating or preventing polyomavirus infections using one or more antibodies.

(a) HCDR1 comprises SEQ ID NO:
113,
HCDR2 comprises SEQ ID NO:
114,
HCDR3 comprises SEQ ID NO:
115,
LCDR1 comprises SEQ ID NO:
116,
LCDR2 comprises SEQ ID NO:
117, and
LCDR3 comprises SEQ ID NO:
118;
(b) HCDR1 comprises SEQ ID NO:
97,
HCDR2 comprises SEQ ID NO:
98,
HCDR3 comprises SEQ ID NO:
99, 131, or 139,
LCDR1 comprises SEQ ID NO:
100,
LCDR2 comprises SEQ ID NO:
101, and
LCDR3 comprises SEQ ID NO:
102;
(c) HCDR1 comprises SEQ ID NO:
1,
HCDR2 comprises SEQ ID NO:
2,
HCDR3 comprises SEQ ID NO:
3,
LCDR1 comprises SEQ ID NO:
4,
LCDR2 comprises SEQ ID NO:
5, and
LCDR3 comprises SEQ ID NO:
6;
(d) HCDR1 comprises SEQ ID NO:
9,
HCDR2 comprises SEQ ID NO:
10,
HCDR3 comprises SEQ ID NO:
11,
LCDR1 comprises SEQ ID NO:
12,
LCDR2 comprises SEQ ID NO:
13, and
LCDR3 comprises SEQ ID NO:
14;
(e) HCDR1 comprises SEQ ID NO:
17,
HCDR2 comprises SEQ ID NO:
18,
HCDR3 comprises SEQ ID NO:
19,
LCDR1 comprises SEQ ID NO:
20,
LCDR2 comprises SEQ ID NO:
21, and
LCDR3 comprises SEQ ID NO:
22;
(f) HCDR1 comprises SEQ ID NO:
25,
HCDR2 comprises SEQ ID NO:
26,
HCDR3 comprises SEQ ID NO:
27,
LCDR1 comprises SEQ ID NO:
28,
LCDR2 comprises SEQ ID NO:
29, and
LCDR3 comprises SEQ ID NO:
30;
(g) HCDR1 comprises SEQ ID NO:
33,
HCDR2 comprises SEQ ID NO:
34,
HCDR3 comprises SEQ ID NO:
35,
LCDR1 comprises SEQ ID NO:
36,
LCDR2 comprises SEQ ID NO:
37, and
LCDR3 comprises SEQ ID NO:
38;
(h) HCDR1 comprises SEQ ID NO:
41,
HCDR2 comprises SEQ ID NO:
42,
HCDR3 comprises SEQ ID NO:
43,
LCDR1 comprises SEQ ID NO:
44,
LCDR2 comprises SEQ ID NO:
45, and
LCDR3 comprises SEQ ID NO:
46;
(i) HCDR1 comprises SEQ ID NO:
49,
HCDR2 comprises SEQ ID NO:
50,
HCDR3 comprises SEQ ID NO:
51,
LCDR1 comprises SEQ ID NO:
52,
LCDR2 comprises SEQ ID NO:
53, and
LCDR3 comprises SEQ ID NO:
54;
(j) HCDR1 comprises SEQ ID NO:
65,
HCDR2 comprises SEQ ID NO:
66,
HCDR3 comprises SEQ ID NO:
67,
LCDR1 comprises SEQ ID NO:
68,
LCDR2 comprises SEQ ID NO:
69, and
LCDR3 comprises SEQ ID NO:
70;
(k) HCDR1 comprises SEQ ID NO:
73,
HCDR2 comprises SEQ ID NO:
74,
HCDR3 comprises SEQ ID NO:
75,
LCDR1 comprises SEQ ID NO:
76,
LCDR2 comprises SEQ ID NO:
77, and
LCDR3 comprises SEQ ID NO:
78;
(l) HCDR1 comprises SEQ ID NO:
81,
HCDR2 comprises SEQ ID NO:
82,
HCDR3 comprises SEQ ID NO:
83,
LCDR1 comprises SEQ ID NO:
84,
LCDR2 comprises SEQ ID NO:
85, and
LCDR3 comprises SEQ ID NO:
86;
(m) HCDR1 comprises SEQ ID NO:
89,
HCDR2 comprises SEQ ID NO:
90,
HCDR3 comprises SEQ ID NO:
91,
LCDR1 comprises SEQ ID NO:
92,
LCDR2 comprises SEQ ID NO:
93, and
LCDR3 comprises SEQ ID NO:
94;
(n) HCDR1 comprises SEQ ID NO:
105,
HCDR2 comprises SEQ ID NO:
106,
HCDR3 comprises SEQ ID NO:
107,
LCDR1 comprises SEQ ID NO:
108,
LCDR2 comprises SEQ ID NO:
109, and
LCDR3 comprises SEQ ID NO:
110;
(o) HCDR1 comprises SEQ ID NO:
121,
HCDR2 comprises SEQ ID NO:
122,
HCDR3 comprises SEQ ID NO:
123,
LCDR1 comprises SEQ ID NO:
124,
LCDR2 comprises SEQ ID NO:
125, and
LCDR3 comprises SEQ ID NO:
126;
(p) HCDR1 comprises SEQ ID NO:
145,
HCDR2 comprises SEQ ID NO:
146,
HCDR3 comprises SEQ ID NO:
147,
LCDR1 comprises SEQ ID NO:
148,
LCDR2 comprises SEQ ID NO:
149, and
LCDR3 comprises SEQ ID NO:
150;
(q) HCDR1 comprises SEQ ID NO:
153,
HCDR2 comprises SEQ ID NO:
154,
HCDR3 comprises SEQ ID NO:
155,
LCDR1 comprises SEQ ID NO:
156,
LCDR2 comprises SEQ ID NO:
157, and
LCDR3 comprises SEQ ID NO:
158;
(r) HCDR1 comprises SEQ ID NO:
161,
HCDR2 comprises SEQ ID NO:
162,
HCDR3 comprises SEQ ID NO:
163,
LCDR1 comprises SEQ ID NO:
164,
LCDR2 comprises SEQ ID NO:
165, and
LCDR3 comprises SEQ ID NO:
166;
(s) HCDR1 comprises SEQ ID NO:
169,
HCDR2 comprises SEQ ID NO:
170,
HCDR3 comprises SEQ ID NO:
171,
LCDR1 comprises SEQ ID NO:
172,
LCDR2 comprises SEQ ID NO:
173, and
LCDR3 comprises SEQ ID NO:
174;
or
(t) HCDR1 comprises SEQ ID NO:
177,
HCDR2 comprises SEQ ID NO:
178,
HCDR3 comprises SEQ ID NO:
179,
LCDR1 comprises SEQ ID NO:
180,
LCDR2 comprises SEQ ID NO:
181, and
LCDR3 comprises SEQ ID NO:
182.

238 more elements

Facts

Application

18/549,974Filed 11 Mar 2022 · us provisional application

Priority

12 Mar 2021

Published

US 2025/0304658 A12 Oct 2025

Granted

30 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 16/081
Against material from viruses: dNA viruses
C07K 16/084
DNA viruses: papillomaviridae ; Polyomaviridae , e.g. SV40, BK virus or JC virus
A61K 31/343
Having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide: condensed with a carbocyclic ring, e.g. coumaran,…
A61K 31/366
Lactones: having six-membered rings, e.g. delta-lactones